Abstract -Controversy has persisted for over a decade whether transcatheter patent foramen ovale (PFO) 
P atent foramen ovale (PFO) closure is a strategy for prevention of strokes presumed to be because of paradoxical embolism. This therapeutic approach has a long history punctuated by controversy and challenges in clinical trial design and execution. 1 The first landmark event was the observation of an unexpected higher frequency of PFO being found in cryptogenic stroke patients. Early observational reports of PFO closure suggested benefit followed by a period of unbridled enthusiasm for PFO closure. Subsequently, professional societies made a plea for randomized trials 2 and there have been 2 rounds of publications of completed randomized trials that have advanced our knowledge, modified guidelines, lead to the first approved PFO device in the United States, and caused a renaissance in the use of PFO closure in carefully selected patients. 3-5 The 3 randomized clinical trials missed their primary end points for the intention to treat population. In RESPECT, significantly fewer recurrent ischemic strokes were seen in the device group when also analyzed in the per-protocol and as-treated patient populations. Professional guidelines and practice advisories subsequently downgraded the indication for PFO closure. 6, 7 A meta-analysis using patient-level data showed a significant treatment benefit with the AMPLATZER PFO Occluder. 8 In addition, a study-level network meta-analysis of all 3 trials demonstrated that treatment with the AMPLATZER PFO Selective PFO Closure After Cryptogenic Stroke Occluder reduced ischemic stroke recurrence more than medical treatment. 9 There were many lessons learned from these initial trials results.
First Round of Randomized Clinical Trials
1. The individual trials were underpowered. 2. Trials had to have longer-term follow-up or more sensitive means of detecting events such as with brain imaging because of the low frequency of recurrent strokes. 3. The type of device had an impact on the safety of the procedure and could be responsible for recurrent strokes by causing atrial fibrillation or thrombus on the left atrial disc. 4 . Patient selection criteria needed to focus on patients likely to have had an embolic mechanism of the index stroke. 5. Transient ischemic attacks should not be the index inclusion event because of the need for an objectively verified primary event of brain infarction. 6. Antiplatelet therapy had become the dominant medication used by the vascular neurology community to prevent recurrent cryptogenic strokes. Therefore, a comparison of device closure versus antiplatelet therapy was needed. 7. Patient with atrial septal aneurysm or large shunts needed to be studied. Atrial septal aneurysm identifies patients more likely to have recurrent strokes. 8. The recruitment and retention of patients in randomized trials was challenging because off-label PFO closure was widely being performed. 9. PFO closure should be considered a targeted secondary prevention therapy that can only prevent strokes from paradoxical embolism. Other mechanisms for recurrent stroke may occur and needed to be identified in clinical trials and prevented in clinical practice by other secondary prevention strategies. 10. Cardiology and neurology collaboration was key to moving the field forward and providing more definitive trial data.
Second Round of Randomized Clinical Trials
The 3 latest trials were published in 2017. [10] [11] [12] An updated systemic review with meta-analysis has been recently published incorporating these new trial results. 13 These trials are compared in terms of study design (Table 1) , patient characteristics (Table 2) , efficacy end points (Table 3) , and safety results (Table 4) . Although the trials had many similarities there are important differences and unique lessons learned that will be discussed. Recurrence) also mandated long-term antiplatelet therapy in the patients randomized to device, whereas RESPECT mandated antiplatelet therapy until 6 months after closure and then left continuation up to the investigative neurologist.
Comparison of Study Design and Execution
RESPECT-LT was the largest trial, started the earliest (August 2003), enrolled for the longest duration (112 months) and had the longest duration of follow-up (mean 5.9 years). Continuation of the RESPECT trial after publication of the initial results in 2013 was prespecified in the protocol. The initial publication represents the primary outcome from RESPECT and was protocol mandated after 25 primary end points had occurred. For RESPECT-LT additional patients were not recruited, but those remaining in the trial from the original 980 enrolled were followed. Therefore, the final results of RESPECT-LT are exploratory from a strict clinical trial perspective but are clinically valuable and were adequate for regulatory approval.
REDUCE was unique in the utilization of pre and postrandomization magnetic resonance imaging (MRI) to detect all strokes, including silent brain infarctions. A second primary end point incorporated the MRI findings. The trial studied 2 Gore devices. The largest number of patients were from Scandinavian countries and the United States.
CLOSE was the only trial having 3 arms: device plus antiplatelet therapy, antiplatelet therapy alone, and oral anticoagulation alone. A broad array (n=11) of PFO closure devices were used in this trial with the Amplatzer PFO Occluder used most commonly (51%). Therefore, CLOSE needs to be considered more of a strategy study of PFO closure than a specific device study. This trial was investigator initiated with funding by the French Ministry of Health. Most patients were enrolled at French centers.
All trials had inclusion criteria that were quite similar in terms of the index stroke being cryptogenic after a thorough evaluation.
The exclusion criteria for the 3 studies did have some important differences. All trials excluded patients with evidence for antiphospholipid antibodies. REDUCE also excluded those with inherited hypercoagulable states but performed these tests only in those with first-degree family members with a history of a thromboembolic event or in those with an unknown family history. RESPECT initially performed testing for the inherited thrombophilias, but this was discontinued at the midpoint of the study and was not an exclusion criteria. CLOSE performed testing for the inherited thrombophilias but did not exclude those with positive testing. CLOSE used a lower threshold (≥30% of lumen diameter) of exclusion of patients with atherosclerosis of the intra and extracranial arteries, whereas RESPECT and REDUCE used a >50% cutoff.
All trials were challenged with slow enrollment taking between 72 to 112 months to complete enrollment. The 72 months in CLOSE comes with the caveat that the budget was insufficient to enroll the planned 900 patients and the steering committee stopped enrollment at 664 patients. Follow-up was then completed at 2 years after cessation of enrollment.
RESPECT had the highest discontinuation rates, whereas CLOSE had the lowest. The degree of missing data was greater in the medical arm reflecting in part patients seeking PFO closure outside of the trial. This factor impacted on both RESPECT and REDUCE but likely more on RESPECT Selective PFO Closure After Cryptogenic Stroke because enrollment started 5 years earlier and was during the period when off-label closure of PFO was widespread. Statistical analyses for missing data were performed for both studies and published in their appendices.
Summary of Patient Characteristics Enrolled in 3 Trials
There are some subtle and major differences in the patients enrolled in each trial that may have influenced the results.
CLOSE enrolled the youngest patient population with the lowest frequency of hypertension, diabetes mellitus, hypercholesterolemia, and past history of previous stroke. Active smoking was highest in CLOSE and a substantial percentage of women were taking oral contraceptives. RESPECT had the highest average age of patients at the time of enrollment and the greatest burden of systemic hypertension, diabetes mellitus, and hypercholesterolemia. At long-term follow-up, the RESPECT population had aged, with 22% now over 60 years of age. Patients enrolled in REDUCE were intermediate between the other 2 trials in terms of these traditional risk factors for stroke.
The Risk of Paradoxical Embolism Score (RoPE) includes age, risk factors, and stroke topography with a score range of 0 to 10: higher scores indicate a high probability of the index stroke being attributable to PFO and lower scores indicate a higher probability of the PFO being incidental (Table 5 ). 14 The average RoPE score of patients in CLOSE was 7.1 in the device arm and 7.4 in the antiplatelet arm. The average RoPE score in RESPECT was 6.7.
CLOSE only enrolled patients with either atrial septal aneurysms or large right-to-left shunts, defined as >30 microbubbles visualized in the left atrium within 3 heartbeats of appearing in the right atrium. Patients enrolled in REDUCE had lower rates of large shunts and atrial septal aneurysm than the other trials although in the medical arm the frequency of atrial septal aneurysm was not assessed. RESPECT included 
Summary of Efficacy Results From 3 Trials
As outlined in Table 3 , the 3 trials provided consistent results for the greater reduction of recurrent ischemic events in those undergoing PFO closure. The absolute rate of recurrent ischemic strokes per year was low, and the absolute greater treatment effect from PFO closure was also small when viewed as a per year metric, however, the absolute reduction of recurrent strokes becomes quite impressive in the 5-to 10-year timeframe. Table 3 shows the Kaplan-Meier derived 5-year event rates in the 2 arms for all 3 trials. The medical arm of the 3 trials has a similar 5-year rate of recurrent ischemic strokes.
RESPECT-LT demonstrated a clinically and statistically significant reduction in the risk of recurrent stroke as detailed in Table 3 . In addition post hoc analyses of RESPECT-LT provide clinically valuable insights into patient selection, the impact of aging of the trial population on the mechanisms of recurrent strokes, and the heterogeneity of treatment effect. All primary end point events in RESPECT-LT were recurrent ischemic strokes with 18 events in the device arm and 28 in the medical arm. Further analysis using the ASCOD phenotyping method (A-atherosclerosis, S-small vessel disease, C-cardioembolic, O-other cause, D-dissection) of these recurrent ischemic strokes was completed to determine if they had a likely cause or if the mechanism was unknown. 15 Using this approach, 13 (28%) of the recurrent ischemic strokes were associated with a determined, non-PFO mechanism and 33 (72%) had no cause identified and thus could be PFO-mediated or truly cryptogenic. Recurrent ischemic stroke of unknown mechanism occurred less often in the device arm (10 events) than the medical arm (23 events). In patients with recurrent strokes who were over 60 years of age at long-term follow-up 7 of the 8 strokes (87%) had an identified mechanism of stroke. In a post hoc subgroup analysis of RESPECT-LT, patients with large shunts or atrial septal aneurysm had a greater treatment effect from PFO closure with a 72% relative risk reduction.
As shown in Table 3 , REDUCE demonstrated superiority of device closure plus antiplatelet thereby in reducing the risk of recurrent ischemic strokes, either clinically apparent or as determined by follow-up MRI imaging, versus antiplatelet therapy alone. The 77% relative risk reduction and the low number needed to treat (28 patients to prevent 1 stroke in 24 months) support the argument that this treatment strategy has clear value. REDUCE confirmed the suspicion that silent brain infarcts occur in these patients. In the PFO closure arm, there were 6 recurrent clinical strokes (1.4%) and 22 recurrent brain infarctions by MRI (5.7%), whereas the medical arm had 12 recurrent clinical strokes (5.4%) and 20 recurrent brain infarctions by MRI. The difference between arms was not significant for silent brain infarctions occurring during follow-up.
The results of CLOSE were dramatic with no recurrent ischemic strokes in the device arm after an average followup of 5.4 years. Unfortunately, the trial's enrollment was prematurely curtailed such that the third randomization arm of oral anticoagulation enabling the comparison of antiplatelet therapy with anticoagulation therapy was underpowered. The Tables 1 through 4 represent the device and antiplatelet arms. The results of the third arm, oral anticoagulant therapy, while underpowered, suggest that anticoagulation may be associated with a lower risk of recurrent stroke than antiplatelet therapy, though this is simply hypothesis generating.
The medical therapy used in the 3 trials was not the same, the outcomes may have been influenced by this factor and these trials were not designed to determine the optimal medical management. In RESPECT ≈20% of patients in the medical arm received oral anticoagulation and CLOSE had an anticoagulation arm. In both trials, there was a suggestion that oral anticoagulation may be more effective in reducing recurrent ischemic strokes than antiplatelet therapy in those not receiving PFO closure.
Summary of Safety Results From 3 Trials
There were no unanticipated adverse device effects or deaths related to the procedure or the device. The safety results of the 3 latest trials are summarized in Table 4 . Adverse events related to the procedure and device were low but some were serious adverse events (SAE). The majority of serious adverse events occurring in the 3 trials were transient and treatable.
There was an imbalance in atrial fibrillation and flutter, including both those classified as serious adverse events and those classified as nonserious adverse events, in the PFO closure arm of all 3 trials. It should be noted that all 3 trials did not use screening long-term monitoring to exclude occult paroxysmal atrial fibrillation that has subsequently become standard of care. Likewise, prolonged monitoring during follow-up in both groups was not performed. Therefore, the detection and quantification of paroxysmal atrial fibrillation was not rigorous in these trials.
Atrial fibrillation or flutter in PFO closure trials must first be examined whether it was caused by the procedure or implanted device by comparison with a control group. Furthermore, this adverse event must be analyzed whether it was a transient or recurring, associated with stroke, and if it Technical success is delivery and release of device; procedure success is implantation without in-hospital serious adverse events; complete closure is no microbubbles in left atrium at rest and with provocative maneuvers; effective closure is <10 microbubbles in left atrium at rest and with provocative maneuvers. For RESPECT-LT, there were 25 atrial fibrillation events in 24 patients in the device arm consisting of 499 patients and 12 in the medical arm consisting of 481 patients. In the device arm, there were 7 events that were periprocedure that resolved before discharge and did not reoccur. Subsequently, during long-term follow-up, there were 18 patients with atrial fibrillation in the device arm and 12 in the medical arm. The rate of atrial fibrillation per 100 patient-years comparing postprocedure device patients and the medical arm patients was not statistically different. There were 4 recurrent ischemic strokes that were related to the emergence of atrial fibrillation; 1 occurred in the device arm, and 3 occurred in the medical management arm.
Details of patients with atrial fibrillation in CLOSE were published in the appendix. In the device group, atrial fibrillation occurred in 10 patients and atrial flutter in 1 patient. Its onset was periprocedure in 3, within 2 weeks of the procedure in 7, and in 1 patient at 147 days after the procedure. It was paroxysmal in all and did not recur in any of the patients during follow-up that ranged from 1.4 to 5.0 years. Oral anticoagulation was initially given to 10 of the 11, was subsequently discontinued in 7, and was continued in 3 at their most recent follow-up. No recurrent strokes associated with atrial fibrillation were reported.
In REDUCE (Table 4) , atrial fibrillation was observed in 6.6% of the device arm patients with a 1.90 rate per 100 patient-years. Of the 29 episodes of atrial fibrillation, there In summary, most atrial fibrillation associated with PFO closure is transient and does not seem to recur, but its occurrence is rarely associated with serious clinical consequences such as ischemic stroke that occurred in 2 out of the 1178 patients randomized to the device arm in the 3 trials. Furthermore, the potential need for anticoagulation after a detected episode of paroxysmal atrial fibrillation is another significant change in patient management that may occur in patients undergoing PFO closure. Finally, some episodes of atrial fibrillation/flutter in the device arm are probably not related to the procedure or device because the control groups had an event rate ranging from 0.4% to 1.9% in the 3 trials.
A higher rate of venous thromboembolic events (VTE) including deep venous thrombosis (DVT) and pulmonary embolism (PE) was observed in the device arm of RESPECT-LT. There were 27 events in the device arm (0.86 events per 100 patient-years) and 6 events in the medical arm (0.22 events per 100 patient-years). An extensive analysis revealed the following key points. No device patients had thrombus seen on the device during the protocol mandated 6-month transesophageal echocardiogram or during any subsequent echocardiograms. Five of the DVT events were temporally associated with the procedure using the 6-month postprocedure window for adjudication of relatedness. In the device arm, 22 of the 27 events occurred late, that is, >6 months postimplant. The greatest predictor of VTE was a prior history of DVT with a 10-fold impact in VTE after the periprocedure time period. Before enrollment in RESPECT 4.0% in the device arm and 3.1% in the medical arm had a history of DVT. The imbalance of postrandomization VTE between treatment arms in RESPECT was associated with the differential use of warfarin, a medication allowed in the medical management arm and was used in ≈20% of patients. Finally, 114 patients who were randomized to the device arm in RESPECT had been initially placed on warfarin immediately after their index stroke by the referring clinician and in all these patients warfarin was stopped per study protocol. The results of the VTE analysis suggests that there was a small subgroup enrolled who had an underlying VTE tendency that became manifest during long-term follow-up especially with differential use of oral anticoagulation. Current VTE guidelines recommend that these patients, identified as having a prior history of VTE before their index ischemic stroke, should be considered for long-term anticoagulation. 16 Device erosion leading to tamponade was not observed in any of the trials but is another rare and serious complication that may occur as the volume of PFO closure procedures increases.
Translating Clinical Trial Results

Into Clinical Practice
The completed clinical trials have established the efficacy and safety of PFO closure but also provide guidance for clinical practice. The following sections provide a blueprint for clinical management using the knowledge gained from these and other trials.
Optimizing the Process of Patient Evaluation and Decision-Making
Maximizing the benefit of PFO closure is linked to optimizing patient selection with a comprehensive initial evaluation and multidisciplinary consultative approach. We suggest a stepwise approach (Table 6 ) to identifying patients with cryptogenic stroke who had an index clinical event that has an enhanced probability of being due to paradoxical embolism. We have established a PFO clinic to optimize the process of patient evaluation, enhance the efficiency of decision-making, and provide the patient with a venue for asking questions. Two specialists jointly see patients, clinical and testing data are reviewed, decisions about treatment options are established with consensus among providers, and recommendations are Figure 1 provides an overview of a PFO clinic's function that incorporates shared decision-making.
Shared decision-making does involve a time commitment for discussions with patients and families, openness on the part of the clinician to accepting their advisory rather than decision-making role, and the ability of the clinician to present the evidence supporting their recommendations with data as well as their clinical judgment. Patient decision aids may make this process more efficient and offer an opportunity to standardize this process while allowing for individualization of risks and benefits as well as incorporating the preferences and values of patients. 17 No such tools presently exist for PFO closure to our knowledge.
Characteristics of the Index Ischemic Stroke
The evaluation leading to the diagnosis of cryptogenic stroke is essential to understand and has been recently reviewed. 18 Cardiologists need to appreciate the challenges inherent in the attempt to determine the mechanism of stroke in the individual patient.
A key question to ask when assessing a patient with an ischemic stroke and a PFO is whether the characteristics of the stroke are consistent with an embolic mechanism. Brain imaging plays a key role as cortical infarcts are more likely to be embolic than lacunar infarctions that are often associated with small vessel disease. The recent classification system of embolic stroke of undetermined source is useful in considering whether a stroke may have been embolic cause. In 2014, this clinical construct was introduced and recently was reviewed. 19 A post hoc analysis of RESPECT-LT, admittedly underpowered, showed a trend with patients who had a deep brain infarct subsequently having neutral outcomes with closure versus medical therapy. This is in contrast to patients with a superficial or cortical stroke who had better outcomes with closure versus medical therapy.
Age and Traditional Vascular Risk Factors
The analysis of the mechanism of recurrent ischemic strokes in RESPECT-LT highlights several key points. First, PFO closure is a targeted therapy for stroke prevention related to paradoxical embolism and does not cure patients from any future strokes because of other mechanisms. Second, aggressive secondary prevention of other potential stroke mechanisms should be part of the comprehensive and individualized approach to patient care. Third, the PFO may be incidental in some patients despite attention to optimizing patient selection. Fourth, some strokes are neither because of paradoxical embolism nor other defined mechanisms and therefore remain truly cryptogenic. Older patients with cryptogenic strokes, that is, >60-yearold cutoff used in these trials, are frequently encountered in clinical practice. Some may have compelling circumstances for considering PFO closure such as those with no or minimal traditional vascular risk factors for stroke (other than age) and PFO characteristics that may be considered high risk, vide infra. On the other hand, it should be remembered that RESPECT-LT demonstrated that the majority of recurrent strokes in those who were >60 years old had a defined mechanism for their strokes. Furthermore, many patients over the age of 60 have a significant burden of traditional vascular risk factors. Advancing age is not likely to eliminate PFOmediated strokes, but the benefit of PFO closure is likely to be less predictable and considerably reduced perhaps to a point where the balance of benefit and risk does not warrant closure in many of these patients. It remains to be defined whether antiplatelet or anticoagulation is the best medical therapy for these patients.
PFO Diagnosis and Characterization
The central role of echocardiography in the detection and characterization of PFO has been reviewed by an expert panel of the American Society of Echocardiography. 20 An initial transthoracic echocardiogram and subsequent transesophageal echocardiogram should be part of the standard evaluation of all patients being considered for PFO closure. The use of transcranial Doppler is likely to grow especially for screening and semi-quantification of right-to-left shunting in practice settings that are removed from echocardiography laboratories. The degree and dynamic nature of shunting may be assessed by transcranial Doppler, color flow Doppler, and agitated saline studies during transthoracic echocardiogram, transesophageal echocardiogram, and intracardiac echocardiography. Standardization of all these techniques is essential because the PFO is a dynamic flap valve rather than a fixedsize defect and shunting may be absent or substantial in the same patient under different conditions. False-negative results can also occur from poor technique and limitations of technologies. There is a spectrum of definitions of what constitutes an atrial septal aneurysm, a large versus small shunt, a small atrial septal defect versus a PFO, and the differentiation of intracardiac versus intrapulmonary shunting. Best practices include understanding the nature of the Valsalva maneuver, the proper timing to assess changes in shunting from resultant changes in the pressure gradient across a PFO, and the need to standardize the use of this important provocative maneuver to diagnose PFO and quantify shunting. 21 The diversity of PFO anatomy and associated structures must be appreciated because they do impact on the assessment of whether a PFO is incidental versus pathogenic, the potential degree of benefit from PFO closure, and device closure techniques. The characterization of both the septum primum and secundum, the degree of overlap between these 2 tissue flaps creating a tunnel, and the presence of a Chiari network and Eustachian valve are key anatomic features that are visualized by ultrasound. A more in-depth understanding of embryology, anatomy of the PFO, and methods to detect and characterize a PFO are available in recent reviews. 22, 23 The noninvasive evaluation of PFO characteristics is often adequate to refer patients for PFO closure, but the invasive assessment often reveals additional information and certainly is key to device sizing.
The importance of PFO characteristics on patient selection and treatment benefit has emerged most clearly from CLOSE and with supportive data from RESPECT-LT. This does not mean that patients without these characteristics should not be considered for PFO closure, but the level of evidence is simply weaker. The RoPE investigative group did not show an association of large shunt size to recurrent stroke risk but the recent randomized trials provide a more compelling argument in favor of the important of PFO characteristics in choosing patients likely to have the greatest benefit from PFO closure. 
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Clinical Clues to Paradoxical Embolism
Past History or Active VTE
In the presence of an intracardiac or intrapulmonary shunt, the third manifestation of VTE, after DVT and PE, is enabled, that is, paradoxical embolism leading to ischemic stroke or other systemic manifestations. Patients with cryptogenic stroke and a PFO should be asked about a history of VTE, have a physical examination to exclude the presence of DVT, and selectively undergo screening tests for both DVT and PE based on this initial evaluation. Venous system evaluation may include lower extremity venous duplex and pelvic vein magnetic resonance venography, though not warranted in all patients with cryptogenic stroke, should be strongly considered if there is any clinical suspicion and an elevated D-dimer. 27 In 1 study of 37 patients with cryptogenic stroke, PFO, and a variety of other conditions, 10 patients were found to have a DVT by imaging with 5 being located in pelvic or calf veins. 28 In clinical practice, there are some patients with a remote history of VTE, but also some who had their stroke in the setting of active VTE. The trials of PFO closure in cryptogenic stroke excluded patients with active VTE. The role of PFO closure in these patients must be individualized and with the knowledge that PFO will only block paradoxical embolism, not prevent DVT or PE. Anticoagulation therapy may be adequate although an individualized assessment needs to consider the added protection of PFO closure from the devastating impact of recurrent stroke and the frequent lapses in anticoagulation therapy because of noncompliance or planned interrupted therapy. The recent guideline on antithrombotic therapy in VTE is an important resource that addresses the nuances of VTE clinical associations, manifestations, and reviews the scientific evidence that supports recommendations on the nature and duration of antithrombotic therapy. 17 Other sites of thrombus formation that could lead to paradoxical embolism should be considered. Examples include right-sided pacemaker leads and indwelling central venous catheters.
Inherited and Acquired Thrombophilia Disorders
Since the early days of PFO closure the role of thrombophilia, a condition that causes an increased risk to form in situ thrombus, has been considered a potentially important link in the pathophysiology of PFO-related ischemic strokes. The utility of performing the extensive and expensive testing looking for inherited and acquired thrombophilias in patients with ischemic stroke has not been proven. Therefore, routine testing in all patients with cryptogenic stroke and PFO is not recommended for the major inherited thrombophilias including protein C deficiency, protein S deficiency, antithrombin deficiency, factor V Leiden, and the prothrombin G20210A gene mutation. 19 In the presence of unprovoked VTE, cryptogenic stroke, and PFO then thrombophilia screening should be considered. At this point, there is simply a paucity of evidence from clinical trials providing additional guidance.
Prothrombotic medications (ie, estrogen-based hormone replacement) and environmental factors (ie, cigarette smoking) are important to identify and modify as part of a comprehensive secondary stroke risk reduction strategy.
RoPE Score
The incidental versus pathogenic PFO is a key issue in patient selection. As outlined in Table 5 , the RoPE score is derived from patient factors including age, presence or absence of traditional vascular risk factors, and neuroimaging findings of the index stroke. 13 It represents a statistical approach to stratifying patients with cryptogenic stroke and PFO into a spectrum of groups that are more likely to have an incidental versus a pathogenic PFO although it has not been studied prospectively.
Occult Paroxysmal Atrial Fibrillation and LongTerm Monitoring
More vigorous exclusion of occult paroxysmal atrial fibrillation is needed than performed in these trials of PFO closure designed years ago. Paroxysmal atrial fibrillation has been identified in a subset of patients (generally older) with cryptogenic stroke using long-term outpatient monitoring. 29, 30 In the younger patient population enrolled in RESPECT, REDUCE, and CLOSE the emergence of atrial fibrillation during extended follow-up was very low. Long-term monitoring should be selectively used especially in older patients or those having other risk factors for atrial fibrillation such as systemic hypertension and obesity.
Regulatory Issues: Devices Approved for PFO Closure
The regulatory journey of devices used for PFO closure has a long history. Approval of multiple devices occurred in many countries where efficacy studies requiring randomization against standard of care were not required. 31 Transient approval by the US Food and Drug Administration (FDA) for the AMPLATZER PFO Occluder and the STARFlex PFO Occluder occurred in 2002 via a Humanitarian Device Exemptions application for patients who had recurrent cryptogenic stroke because of presumed paradoxical embolism through a PFO and who had failed conventional drug therapy. 32 Subsequently, this Humanitarian Device Exemptions application was withdrawn in 2006 when the number of patients eligible exceeded the number allowed under the Humanitarian Device Exemptions pathway. October 28, 2016, FDA granted premarket approval for the AMPLATZER PFO Occluder. [33] [34] [35] The specific indications for use and a schematic of the device are shown in Figure 2 . The FDA recently published their analysis of RESPECT and the process leading to their approval decision. 36 The Gore HELEX device is no longer available and has been replaced by the Gore CARDIOFORM device that is currently FDA approved for closure of secundum atrial septal defects. FDA approval of this device for PFO closure is under consideration using the results of REDUCE.
The randomized clinical trials in PFO closure and other studies of device comparison have documented that all devices are not the same particularly with safety outcomes. Therefore, use of devices other than the 2 adequately studied in the randomized trials should be approached with caution.
Next Steps
The rational dispersion and appropriate use of PFO closure technologies are now critically important. The potential of inappropriate use of PFO closure is high given that stroke is common and incidental PFOs are found in ≈25% of the adult population. Performing this procedure in patients likely to have incidental PFO does not translate to a decreased risk of recurrent stroke but exposes the patient to the risks of the procedure and device.
The completion of the 3 randomized trials described in this review is but one step in the process of bringing this therapy to patients. Table 7 outlines the additional steps needed to complete this process.
There are many unresolved questions requiring further investigation. Older patients with a PFO and cryptogenic stroke are particularly challenging in determining when PFO closure should be offered. The role of thrombophilia and overt VTE remain incompletely studied about their impact on the management of patients with cryptogenic stroke and PFO. Studies of direct oral anticoagulants versus antiplatelet medications are underway for secondary prevention after embolic strokes of unknown cause. There are some challenging PFO anatomies for which the type, size, and location of the device has not been standardized. The process of evaluation, treatment, and follow-up of these patients can follow the multidisciplinary approach used in RESPECT, but how well this translates to real-world practice remains to be determined. There is no evidence to support the use of PFO closure as a primary prevention treatment.
Clinicians and patients now have data and insights gained from multiple studies that should guide the appropriate use of this form of secondary prevention treatment. The tipping point for PFO closure has now been reached.
